Loading
GI
Genprex, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by VACZY CATHERINE M, was filed 24 Apr 2023.
Genprex, Inc.: what insiders have been doing
Genprex, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Genprex, Inc. logged 9 filings by 5 insiders.
The flow runs one way only: 2 sales worth €19, from 1 insider, and no purchase. Biggest ticket of the year: €10, sold by Longnecker Brent M and made public on 15 April 2026 (0.0000% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 9 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Since 2018, the database holds 8 purchases and 2 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
41
Thresholds
n/a
Buy Volume
€499,825
8 ops. · all time
Sell Volume
€19
2 ops. · all time
Who traded when
BuySaleBrent M. Longnecker2 sales
Since the insiders bought
- -93.2%Entry US$35,992.00 · Close at T+365 US$2,431.00
- -93.2%Entry US$35,992.00 · Close at T+365 US$2,431.00
- -57.7%Entry US$214,280.00 · Close at T+365 US$90,640.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.06
Analyst consensus
Income statement
EBITDA-US$15.5M
Net income-US$16.2M0.0% margin
Valuation
P/Book0.1x
Beta-0.98
Balance sheet & cash
Market capUS$1.7M
Free Cash Flow-US$15.3M
Profitability & ownership
ROE-203.9%
ROA-94.5%
% insiders0.2%
% institutions1.7%
Last declaration on 15 April 2026
Declarations41 total
8 shares@ US$1.230.0000% mcap44.4% of flowCommon StockSEC:0001437749-26-012463:0
10 shares@ US$1.230.0000% mcap55.6% of flowCommon StockSEC:0001437749-26-012463:1
7,168 shares@ US$2.0065.2% of flowCommon StockSEC:0001437749-26-006154:0
9,330 shares@ US$2.0067.6% of flowCommon StockSEC:0001437749-26-006153:0
9,000 shares0Common StockSEC:0001437749-25-038736:0
45,000 shares0Common StockSEC:0001437749-25-038734:0
9,000 shares0Common StockSEC:0001437749-25-038733:0
9,000 shares0Common StockSEC:0001437749-25-038732:0
28,500 shares0Common StockSEC:0001437749-25-038735:0
4,500 shares@ US$0.22794.7% of flowCommon StockSEC:0001437749-25-021819:0
5,775 shares@ US$0.22794.8% of flowCommon StockSEC:0001437749-25-021817:0
395 shares@ US$0.410.7% of flowCommon StockSEC:0001437749-25-004464:0
585 shares@ US$0.411.2% of flowCommon StockSEC:0001437749-25-004466:0
4,750 shares0Common StockSEC:0001437749-24-036886:0
4,750 shares0Common StockSEC:0001437749-24-036882:0
4,750 shares0Common StockSEC:0001437749-24-036884:0
18,250 shares0Common StockSEC:0001437749-24-036878:0
29,375 shares0Common StockSEC:0001437749-24-036880:0
1,126 shares@ US$4.4019.7% of flowCommon StockSEC:0001437749-24-005055:0
2,642 shares@ US$4.4037.1% of flowCommon StockSEC:0001437749-24-005058:0
1,319 shares@ US$4.4028.9% of flowCommon StockSEC:0001437749-24-005062:0
123,795 shares0Common StockSEC:0001437749-23-018939:0
123,795 shares0Common StockSEC:0001437749-23-018943:0
123,795 shares0Common StockSEC:0001437749-23-018941:0
20,000 shares@ US$1.0739100.0% of flowCommon StockSEC:0001437749-23-010869:0
Canonical exit: 20 Jul 2023 (T+90)
25 of 41 declarations
About Genprex, Inc.
Genprex, Inc. is a biopharmaceutical company focused on developing gene therapies for cancer treatment. It is listed on NASDAQ under the ticker GNPX.
